Powder: -20°C for 3 years | In solvent: -80°C for 1 year
BVT948 是一种蛋白酪氨酸磷酸酶抑制剂,还可以抑制赖氨酸甲基转移酶 SETD8 (KMT5A) 和几种细胞色素 P450 (P450) 同工型。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 315 | 现货 | ||
5 mg | ¥ 747 | 现货 | ||
10 mg | ¥ 1,080 | 现货 | ||
25 mg | ¥ 1,680 | 现货 | ||
50 mg | ¥ 2,230 | 现货 | ||
100 mg | ¥ 3,570 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 822 | 现货 |
产品描述 | BVT948 is a protein tyrosine phosphatase (PTP) inhibitor.It can also inhibit lysine methyltransferase SETD8 (KMT5A) and several cytochrome P450 (P450) isoforms. |
体外活性 | BVT948 inhibits TPA-induced MMP-9 up-regulation in a dose-dependent manner. BVT948 does not affect the MAPK phosphorylation by TPA. Treatment with BVT948 diminishes the TPA-induced cell invasion by 50%[3]. BVT948 appears to be an effective inhibitor of both protein tyrosine phosphatases (PTP activity and P450 activity)[1]. BVT948 efficiently and selectively suppresses cellular H4 lysine 20 (H4K20me1) at doses lower than 5 μM within 24 h. Results show that the effect of BVT948 (BVT.948) is to strengthen the insulin signal and has no effects on the duration of the signal. The cells treated with BVT948 recapitulate cell-cycle-arrest phenotypes similar to what are reported for knocking down SETD8 by RNAi[2]. Treatment of MCF-7 cells with 0.5, 1 or 5 μM of BVT948 for 24 h does not cause any significant changes in cell viability. Treatment with BVT948 inhibits TPA-stimulated NF-κB binding activity, but not AP-1 binding activity. |
体内活性 | Compare with vehicle-treated controls, BVT948 (BVT.948, 3 μmol/kg) significantly enhances glucose clearance from the blood stream in response to insulin[1]. |
分子量 | 241.24 |
分子式 | C14H11NO3 |
CAS No. | 39674-97-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 100 mg/mL (414.52 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 4.1452 mL | 20.7262 mL | 41.4525 mL | 103.6312 mL |
5 mM | 0.829 mL | 4.1452 mL | 8.2905 mL | 20.7262 mL | |
10 mM | 0.4145 mL | 2.0726 mL | 4.1452 mL | 10.3631 mL | |
20 mM | 0.2073 mL | 1.0363 mL | 2.0726 mL | 5.1816 mL | |
50 mM | 0.0829 mL | 0.4145 mL | 0.829 mL | 2.0726 mL | |
100 mM | 0.0415 mL | 0.2073 mL | 0.4145 mL | 1.0363 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
BVT948 39674-97-0 Chromatin/Epigenetic Metabolism Phosphatase P450 Histone Methyltransferase Cytochrome P450 Inhibitor BVT 948 BVT-948 CYPs inhibit inhibitor